EN DE
Watch Innova Captab Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Innova Captab Limited (INNOVACAP) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Innova Captab Limited stock ₹405, price ₹1,172, that is 65.5% below the price, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE0DUT01020

IC Innova Captab Limited logo Broad data Nov 11, 2026

Innova Captab Limited

INNOVACAP · NSE

Far too expensive (fair value 66% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Generates free cash flow 
0.3% dividend yield · Well covered
Broad data 
Last quarter vs. a year ago: revenue +34%, profit +42%. 
Quality 51/100 
Expensive Growth (revenue 5y +31.4 %/yr in INR) 
Thin margins · 8.8% net margin (TTM) 
Moderate moat 48/100 · thin data
Fair value ₹404.95 · Strongly overvalued 
Trails peers (5/14) 
Watch Innova Captab Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,298 ₹448.22 Fair Value ₹404.95 Dec 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

34‑month range ₹448.22 – ₹1,298 · fair‑value band ₹154.99 – ₹582.21 · the ₹1,172 price screens above the ₹404.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Innova Captab in your weekly email

Every Wednesday you see whether Innova Captab is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies.

Show moreShow less

It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals.

The company sells its branded generic products through a network of distributors and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.

Stock analysis

Innova Captab Limited (INNOVACAP) currently trades at ₹1,172, while our model-based Fair Value estimate is ₹404.95, 66% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹749.68 per share, and 0 of the 26 models we run sit above the ₹1,172 price.

Bear case: the Economic Profit group reads lowest at ₹140.93, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹154.99 (bear) to ₹582.21 (bull), the price of ₹1,172 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Innova Captab Limited reported revenue of ₹16.0B in FY2026 versus ₹8.0B in FY2022, a compound +19.0%/yr. Reported net income was ₹1.4B in FY2026, compounding +21.8%/yr from FY2022.

Key figures

Market cap ₹67.1B (≈ $712M) Small · P/E ratio 43.6 · P/S ratio 3.83 · EPS (TTM) ₹26.91 · Dividend yield 0.3% · Net margin 8.8% · Return on equity 13.8% · Return on assets (EBIT) 13.0% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 82% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −66%, INNOVACAP screens richer than that median.

Fair Value models

Bear ₹154.99 Fair Value ₹404.95 Bull ₹582.21
Price ₹1,172 · Downside -65.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹15.07 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹154.99 ₹170.75 ₹209.77 76
FCF DCF ₹48.57 ₹79.99 ₹169.33 75
Growth DCF ₹43.30 ₹84.25 ₹155.33 75
All 26 models by family
DCF Models
FCF DCF ₹48.57 ₹79.99 ₹169.33 75
Owner Earnings ₹27.09 ₹83.79 ₹178.62 70
5Y Revenue Exit ₹160.82 ₹346.29 ₹723.87 67
5Y EBITDA Exit ₹222.40 ₹474.63 ₹954.11 70
5Y P/E Exit ₹234.99 ₹596.83 ₹1,083 67
10Y Revenue Exit ₹103.89 ₹304.97 ₹495.94 64
10Y EBITDA Exit ₹146.88 ₹404.95 ₹906.42 62
10Y P/E Exit ₹154.17 ₹425.39 ₹920.22 58
Earnings-Based
Graham-Dodd ₹167.45 ₹1,168 ₹1,639 63
Lynch FV ₹396.35 ₹566.21 ₹736.07 61
PEG = 1.0 ₹396.35 ₹566.21 ₹736.07 57
EPV ₹96.65 ₹111.11 ₹122.62 74
Dividend Discount
Gordon GGM ₹12.74 ₹20.29 ₹25.38 69
DDM Multi-Stage ₹12.74 ₹19.72 ₹21.91 67
Multiples
P/E Multiple ₹406.31 ₹541.75 ₹677.19 63
P/S Multiple ₹313.97 ₹418.63 ₹523.28 58
P/B Multiple ₹632.60 ₹843.47 ₹1,054 55
EV/EBIT ₹307.40 ₹429.66 ₹551.92 66
EV/EBITDA ₹325.57 ₹453.89 ₹582.21 67
EV/Revenue ₹202.40 ₹314.59 ₹426.78 53
Asset-Based
NCAV (Graham) ₹20.34 ₹30.82 ₹38.53 54
Growth DCF
Growth DCF ₹43.30 ₹84.25 ₹155.33 75
Rev-Margin DCF ₹160.82 ₹395.51 ₹760.75 68
Economic Profit
Residual Income ₹154.99 ₹170.75 ₹209.77 76
ROIC Compounder ₹96.65 ₹111.11 ₹122.62 72
Growth Earnings
Growth-Adj P/E ₹524.78 ₹749.68 ₹974.59 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 51/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 53
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 18
Do the profits arrive as real cash?
Financial strength 68
Debt, balance sheet and risk of trouble
Investment 29
Does it invest with discipline instead of growing at any price?
Low Volatility 76
How calm the share price moves, does not count
Price momentum 83
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 91
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+29.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.4%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.1%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+32.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.5%
Dividend (yield on the price)0.3%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 10%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+70.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +63.9% a year for the price.

INNOVACAP screens overvalued: fair value 66% below the price. Compare with Merck KGaA →

Compare Innova Captab Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks

Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 51 · Below median
Fair Value upside −65.5% · Bottom 25%
Profitability
Return on equity (12 months) 13.8% · Top 25%
Return on assets 7.7% · Top 25%
Net margin (12 months) 8.8% · Above median
Operating margin (12 months) 13.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 33.9% · Top 25%
Dividend yield (12 months) 0.3% · Bottom 25%
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 43.6× · Priciest 25%
P/B 6.15× · Priciest 25%
P/S (12 months) 3.83× · Pricier than median
Price / free cash flow (fiscal year) 195.3× · Priciest 25%
EV/EBITDA 27.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)100 · sector 26
PAST (return on equity)55 · sector 25
HEALTH (low debt)90 · sector 96
DIVIDEND (yield)5 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Innova Captab Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Innova Captab Limited Fair Value". https://www.fairvalue-calculator.com/stock/INNOVACAP

Frequently asked questions

Is Innova Captab Limited (INNOVACAP) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ₹404.95 versus a price of ₹1,172, about 66% lower (overvalued).
What is the fair value of INNOVACAP?
Our model-based fair value for Innova Captab Limited is ₹404.95 (as of Nov 11, 2026), built from audited fundamentals. The current price: ₹1,172.
What is the quality score of INNOVACAP?
Innova Captab Limited has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Innova Captab Limited (INNOVACAP)?
Our model-based price target is the fair value of ₹404.95 (as of Nov 11, 2026) from 26 valuation models. Cautious scenario ₹154.99, optimistic scenario ₹582.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Innova Captab Limited stock forecast for 2026?
Our models put fair value at ₹404.95, about 66% lower versus a price of ₹1,172 (overvalued). Cautious scenario ₹154.99, optimistic scenario ₹582.21. The calculation is refreshed regularly with new filings.
What is the revenue of Innova Captab Limited (INNOVACAP)?
Innova Captab Limited reported trailing-twelve-month revenue of about ₹17.5B (latest available figure, as of Nov 11, 2026).
Does Innova Captab Limited pay a dividend?
Innova Captab Limited currently shows a dividend yield of 0.26% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of Innova Captab Limited (INNOVACAP) and when is the ex-dividend date?
Innova Captab Limited pays a dividend of ₹3.00 per share a year, a dividend yield of 0.3%. The last ex-dividend date was Jan 30, 2026. The payout ratio is 11.1% of earnings. Free cash flow covers the dividend 2.00 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Innova Captab Limited (INNOVACAP)?
For today's price to be fair in a discounted-cash-flow model, Innova Captab Limited would have to grow free cash flow by 70.7 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 31.4 % per year. As of Nov 11, 2026.
What discount rate (WACC) does the fair value of INNOVACAP use?
Our models discount Innova Captab Limited at 13.9 %: a base by market capitalisation (small), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Innova Captab Limited that is +70.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has Innova Captab Limited (INNOVACAP) delivered so far?
Over the past 5 years revenue at Innova Captab Limited grew 31.4 % a year. The price currently implies free-cash-flow growth of +70.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Innova Captab Limited (INNOVACAP) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Innova Captab Limited (+70.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Innova Captab Limited (INNOVACAP)?
The free-cash-flow yield on the price is 0.51 %: that much free cash flow Innova Captab Limited produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Innova Captab Limited (INNOVACAP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Innova Captab Limited it is ₹404.95 per share (as of Nov 11, 2026), against a price of ₹1,172. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Innova Captab Limited stock overvalued or undervalued in 2026?
As of Nov 11, 2026, INNOVACAP trades above its calculated fair value: price ₹1,172, fair value ₹404.95, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INNOVACAP?
No. The price is what the market pays today (₹1,172); the fair value is what the company's own numbers justify (₹404.95). For Innova Captab Limited the two are ₹767.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Innova Captab Limited worth?
The market values Innova Captab Limited at about ₹67.1B (market capitalisation, as of Nov 11, 2026). Per share that is ₹1,172; our models calculate a fair value of ₹404.95 per share.
What do the bullish and bearish scenarios say about INNOVACAP?
Our models span a range for Innova Captab Limited: cautious scenario ₹154.99, base ₹404.95, optimistic ₹582.21 per share (as of Nov 11, 2026, price ₹1,172). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of INNOVACAP?
Innova Captab Limited trades at a price-to-earnings ratio of 43.6 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹404.95 is built from several models across several years. Other multiples: P/B 6.2, P/S 3.8, EV/EBITDA 27.0.
How solid is the balance sheet of Innova Captab Limited (INNOVACAP)?
Balance-sheet figures for Innova Captab Limited (as of Nov 11, 2026): return on equity 13.8%, debt of 0.20 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is INNOVACAP from its 52-week high?
Innova Captab Limited trades at ₹1,172, about 10% below its 52-week high of ₹1,298 and 82% above the low of ₹642.85 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹404.95 is for.
Which stocks are comparable to Innova Captab Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Innova Captab Limited stock attractive at the current price?
The data as of Nov 11, 2026: price ₹1,172, calculated fair value ₹404.95 (−66%), Quality Score 51/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INNOVACAP calculated?
We run Innova Captab Limited through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹404.95 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Innova Captab Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Innova Captab Limited (INNOVACAP)?
The closing price on Nov 13, 2026 was ₹1,172. Our model-based fair value is ₹404.95, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Innova Captab Limited right now?
The price sits above even our optimistic bull case (₹582.21). The favourable scenario is already priced in. The model range is unusually wide (₹154.99 to ₹582.21). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Innova Captab Limited

How large is the market capitalisation of Innova Captab Limited (INNOVACAP)?
The market capitalisation of Innova Captab Limited is ₹67.1B (≈ $712M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Innova Captab Limited (INNOVACAP)?
The price-to-sales ratio of Innova Captab Limited is 3.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Innova Captab Limited (INNOVACAP)?
Earnings per share at Innova Captab Limited are ₹26.91 (price ÷ EPS = P/E 43.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Innova Captab Limited (INNOVACAP)?
The dividend yield of Innova Captab Limited is 0.3% (payout 11.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Innova Captab Limited (INNOVACAP)?
The net margin of Innova Captab Limited is 8.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Innova Captab Limited (INNOVACAP)?
The return on equity (ROE) of Innova Captab Limited is 13.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Innova Captab Limited (INNOVACAP)?
On an EBIT basis the return on assets of Innova Captab Limited is 13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Innova Captab Limited (INNOVACAP)?
The operating margin of Innova Captab Limited is 13.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Innova Captab Limited (INNOVACAP)?
Revenue at Innova Captab Limited is growing 33.9% versus a year earlier (3y avg +20.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Innova Captab Limited (INNOVACAP)?
Earnings per share at Innova Captab Limited are growing 42.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Innova Captab Limited (INNOVACAP) carry?
The net debt of Innova Captab Limited is ₹3.4B (fiscal year 2026, ≈ 9.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Innova Captab Limited in the live analysis

One click puts Innova Captab Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.